Fig. 2From: A pooled analysis of mesenchymal stem cell-based therapy for liver diseaseChanges in liver function from baseline to week 48. A total of 983 patients received mesenchymal stem cell (MSC)-based therapy, and 557 patients underwent conventional supportive treatment. After treatment, the model for end-stage liver disease (MELD) score, and the alanine aminotransferase (ALT), total bilirubin (TBiL), prothrombin time (PT), and international normalized ratio (INR) levels showed decreasing trends, while the albumin (ALB), prothrombin activity (PTA), and cholinesterase (CHE) levels showed increasing trends. Data are means ± SEMBack to article page